Vetter, a global CDMO, is making additional investments as part of its long-lead goals for continued expansion and to support customer needs. The company is investing €230 million in its new production building, which is currently under construction at its global corporate headquarters site in Ravensburg, Germany. The building will feature several new commercial filling lines to increase aseptic manufacturing capacity for its global customer base. Vetter plans to install the first cleanrooms by the end of 2024.
Vetter Managing Director Thomas Otto, said, “Our new production building signifies our ongoing dedication to support the needs of our customers concerning their complex injectable drug products with regards to packaging systems, specific process requirements and batch sizes. This is just one of several investments we are currently undertaking to manage our sustainable growth.”
Further investments include the increase of lab space for analytical services, the expansion of filling capacity through new commercial production lines at other sites in the EU, the expansion in cool storage and warehousing, as well as a new technical equipment warehouse. Additionally, the company is optimizing infrastructure at all global sites to further develop processes, and developing new compounding and preparation rooms for the handling of incoming and outgoing products.
“In our industry, the needs of our customers and the patients they serve continue to evolve,” said Vetter Managing Director Peter Soelkner. “Our job as a leading CDMO is to act as a strong partner, take the proactive steps necessary to identify relevant industry trends, and thus, to meet the evolving demands of the market through offering adequate resources. Over the coming years, we will continue to make further investments to stay on track with this commitment that we have made as a service provider, from the early development phase to aseptic fill and finish through assembly and packaging services.”
